Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Jaclyn A. Smith, Michael M. Kitt, Alyn H. Morice, Surinder S. Birring, Lorcan P. McGarvey, Mandel R. Sher, Yu Ping Li, Wen Chi Wu, Zhi Jin Xu, David R. Muccino, Anthony P. Ford, Jaclyn Smith, Surinder Birring, James Hull, Warner W. Carr, Alan B. Goldsobel, Gary N. Gross, John R. Holcomb, Iftikhar Hussain, Mandel SherSelwyn Spangenthal, William Storms, Alyn Morice, David Elkayam, Gary C. Steven, James Krainson, Faisal Alfonso Fakih, Jonathan Matz, Gregory Daniel Brooks, Thomas Casale, Gary D. Berman, John J. Condemi, Leon S. Greos, Shaila U. Gogate, Ellen R. Sher, Jason H. Friesen, Eric J. Schenkel, David Isaac Bernstein, Jonathan Corren, Krishna Sundar, Mark H. Gotfried, Anthony Montanaro, William R. Lumry, Niran J. Amar, Michael S. Kaplan, Bruce M. Prenner, Thomas R. Murphy, James S. Good, Sean Parker, Tim Harrison, Ian Pavord, Christopher Brightling, Ratko Djukanovic, Douglas McQuaid, Michael Denenberg, Neil A. Ettinger, Vivek Iyer

Research output: Contribution to journal › Article › peer-review

159 Scopus citations

Fingerprint

Dive into the research topics of 'Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial'. Together they form a unique fingerprint.

Medicine & Life Sciences